- Home
- EMX vs GOSS Comparison
EMX vs GOSS Comparison
Compare EMX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMX
- GOSS
- Stock Information
- Founded
- EMX N/A
- GOSS 2015
- Country
- EMX Canada
- GOSS United States
- Employees
- EMX N/A
- GOSS N/A
- Industry
- EMX
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- EMX
- GOSS Health Care
- Exchange
- EMX Nasdaq
- GOSS Nasdaq
- Market Cap
- EMX 338.0M
- GOSS 347.8M
- IPO Year
- EMX N/A
- GOSS 2019
- Fundamental
- Price
- EMX $3.33
- GOSS $1.96
- Analyst Decision
- EMX Strong Buy
- GOSS Strong Buy
- Analyst Count
- EMX 2
- GOSS 4
- Target Price
- EMX $5.38
- GOSS $8.50
- AVG Volume (30 Days)
- EMX 388.2K
- GOSS 3.1M
- Earning Date
- EMX 08-11-2025
- GOSS 08-05-2025
- Dividend Yield
- EMX N/A
- GOSS N/A
- EPS Growth
- EMX N/A
- GOSS N/A
- EPS
- EMX 0.04
- GOSS N/A
- Revenue
- EMX $29,864,000.00
- GOSS $40,237,000.00
- Revenue This Year
- EMX $7.32
- GOSS N/A
- Revenue Next Year
- EMX N/A
- GOSS $63.97
- P/E Ratio
- EMX $74.57
- GOSS N/A
- Revenue Growth
- EMX N/A
- GOSS N/A
- 52 Week Low
- EMX $1.59
- GOSS $0.66
- 52 Week High
- EMX $3.39
- GOSS $2.23
- Technical
- Relative Strength Index (RSI)
- EMX 71.52
- GOSS 58.35
- Support Level
- EMX $3.01
- GOSS $1.67
- Resistance Level
- EMX $3.39
- GOSS $2.00
- Average True Range (ATR)
- EMX 0.11
- GOSS 0.17
- MACD
- EMX 0.02
- GOSS -0.02
- Stochastic Oscillator
- EMX 88.00
- GOSS 52.21
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.